July 19th, 2008
ImClone Systems, Inc.’s advanced colorectal cancer drug has now received regulatory approval in Japan.
ERBITUX(R) (cetuximab) has received marketing authorization in Japan for use in treating patients with advanced or metastatic colorectal cancer (mCRC).
Specifically, this approval allows for the use of ERBITUX to treat patients with epidermal growth factor receptor (EGFR)-positive, curatively unresectable (inoperable), advanced or […]
By Gloria Gamat -- 0 comments
March 14th, 2008
An allergic reaction to the cancer drug cetuximab has been found.
Sometimes the reaction includes anaphylaxis, a life-threatening condition characterized by a drop in blood pressure, fainting, difficulty breathing, and wheezing.
Now researchers funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have discovered that specific pre-existing antibodies […]
By Gloria Gamat -- 2 comments
April 25th, 2007
When all other treatment options for colorectal cancer have been exhausted to no significant effect, cetuximab is the effective treatment option.
Such were the suggestion confirmed by a research study recently presented at the 2007 Annual Meeting of the American Association for Cancer Research
According to Derek Jonker, M.D., assistant professor at the University of Ottawa and […]
By Gloria Gamat -- 3 comments
January 22nd, 2007
Preliminary findings of a new study designed by researchers at the University of Maryland Medical Center found that adding the chemotherapy drug cetuximab (brand name Erbitux) to radiation therapy and chemotherapy may help some patients with head and neck cancer to live longer.
According to Mohan Suntharalingam, M.D., lead author of the study and a radiation […]
By Gloria Gamat -- 0 comments
Recent Comments